Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 12 Non-Muscle Invasive Bladder Neoplasms 4 Carcinoma, Transitional Cell 2 Ureteral Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Kidney Neoplasms 1 Hematuria 1 Carcinoma in Situ 1

Interventions

Specimen Handling 8 pembrolizumab 7 enfortumab vedotin 7 Magnetic Resonance Spectroscopy 6 avelumab 4 Nivolumab 4 Gemcitabine 3 cabozantinib 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 Cisplatin 2 Carboplatin 2 CTLA-4 Antigen 2 Biopsy 2 vinflunine 1 tremelimumab 1 tocilizumab 1 tamibarotene 1 relatlimab 1 eribulin 1 erdafitinib 1 durvalumab 1 copanlisib 1 atezolizumab 1 Watchful Waiting 1 Standard of Care 1 Propranolol 1 Practice Guidelines as Topic 1 Plasmapheresis 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Cystoscopy × 1 year × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡